Form 8-K - Current report:
SEC Accession No. 0001140361-23-002460
Filing Date
2023-01-24
Accepted
2023-01-23 20:29:12
Documents
13
Period of Report
2023-01-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10046922_8k.htm   iXBRL 8-K 26855
2 EXHIBIT 99.1 brhc10046922_ex99-1.htm EX-99.1 22300
  Complete submission text file 0001140361-23-002460.txt   196676

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aqst-20230106.xsd EX-101.SCH 3869
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aqst-20230106_lab.xml EX-101.LAB 23291
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aqst-20230106_pre.xml EX-101.PRE 16555
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc10046922_8k_htm.xml XML 4225
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 23545633
SIC: 2834 Pharmaceutical Preparations